Incyte Corporation (NASDAQ: INCY) fell 10.9% to $125.48. The Food and Drug Administration on Friday declined to approve Eli Lilly and Co and Incyte arthritis drug Olumiant. Piper Jaffray downgraded Incyte from overweight to neutral. Share volume totaled 3.5 million, compared to an all-day average of 2.5 million
